Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2826592 | 0.84 | HSD17B10 (0.67) | HSD17B10MEN1KMT2AMAPK8MAPK9 | |
| SCHEMBL9159002 | 0.84 | HSD17B10 (0.49) | HSD17B10MEN1KMT2AALDH1A1RAD52 | |
| SCHEMBL28142858 | 0.82 | HSD17B10 (0.50) | HSD17B10MEN1KMT2AALDH1A1RAD52 | |
| SCHEMBL2826584 | 0.79 | GAA (0.64) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL29907950 | 0.79 | GAA (0.64) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL4856579 | 0.78 | MTNR1A (0.49) | ALDH1A1GAAMAPTTSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL30772166 | 0.77 | GAA (0.47) | HSD17B10MEN1KMT2AALDH1A1RAD52 | |
| SCHEMBL2190989 | 0.77 | DPP4 (0.49) | HSD17B10MEN1KMT2AALDH1A1GAA | |
| SCHEMBL2302222 | 0.76 | CYP3A4 (0.45) | MEN1KMT2ATSHRCTSD | |
| SCHEMBL3003760 | 0.76 | MAPT (0.57) | MEN1KMT2AALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7119090-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040106630-A1 | Bicyclic protein kinase inhibitors | SUGEN, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040106618-A1 | Bicyclic protein kinase inhibitors | SUGEN, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2004-04-08 | — | — | US | disclosed |
| US-6696463-B2 | FOR THERAPY OF CELL PROLIFERATION, DIFFERENTIATION OR GROWTH DISORDERS, CANCER | SUGEN, INC. | 2004-02-24 | — | — | US | disclosed |
| EP-1082305-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| US-6051593-A | USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN TYROSINE KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0984930-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | Sugen, Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999061422-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1998050356-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | ABL1, LCK, PNCK | HSD17B10 3091/4885MEN1 3839/4885KMT2A 2047/4885 |
| US-20040106618-A1 | Bicyclic protein kinase inhibitors | MAP3K20, MAP4K3, MAP4K2 | HSD17B10 1991/4885MEN1 3295/4885KMT2A 2711/4885 |
| US-20040106630-A1 | Bicyclic protein kinase inhibitors | MAP3K20, MAP4K3, MAP4K2 | HSD17B10 1991/4885MEN1 3295/4885KMT2A 2711/4885 |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | HSD17B10 2658/4885MEN1 4639/4885KMT2A 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.